Steglujan is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes. It is used together with diet and exercise in the following patients: - patients whose blood glucose levels are not satisfactorily controlled with the diabetes medicines metformin and/or a sulphonylurea, in combination with either ertugliflozin or sitagliptin; - patients who are already taking ertugliflozin and sitagliptin as separate tablets. Steglujan contains the active substances ertugliflozin and sitagliptin.
Therapeutic Indication
### Therapeutic indication Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: - when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control. - in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.
Therapeutic Area (MeSH)
ATC Code
A10BD24
ATC Item
sitagliptin and ertugliflozin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sitagliptin phosphate monohydrate | N/A | 西格列汀 |
| ertugliflozin l-pyroglutamic acid | N/A | Ertugliflozin pidolate |
EMA Name
Steglujan
Medicine Name
Steglujan
Aliases
N/ANo risk management plan link.
